Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

SUMMARY: Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In this study of postmenopausal women with low BMD, a second course of romosozumab following a period off treatment or on denosumab increased or maintained BMD, respectively, and was well tolerated, providi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kendler, D.L., Bone, H.G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S., Dinavahi, R.V., Libanati, C., Grauer, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877701/
https://www.ncbi.nlm.nih.gov/pubmed/31628490
http://dx.doi.org/10.1007/s00198-019-05146-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877701/
https://www.ncbi.nlm.nih.gov/pubmed/31628490
http://dx.doi.org/10.1007/s00198-019-05146-9

Ejemplares similares